EPAS1 and hereditary clear cell renal cell carcinoma: Therapeutic promotion of the formation and degradation of PHD2.Fe(III).2OG.HIF2α complexes using small-molecules may be a complementary strategy for treatment of VHL mutant associated renal cell carcinoma (Fig. S15).